Neuropsychiatric disorders and inflammation are closely intertwined and possibly power each other in a bidirectional loop. Ace Therapeutics is committed to providing advanced technology and expertise to help clients investigate the neuroimmune mechanisms of psychiatric disorders, thereby providing a new scientific basis for the prevention, diagnosis, and treatment of psychiatric disorders.

Fig. 1 Common immune pathways in MDD and AD. (Herman, F. J. et al., 2019)

Our Neuroimmune Mechanisms Research Services of Psychiatric Disorders

With rich research experience and advanced experimental platforms, we can provide professional services to our clients in the following areas:

• Research on the immune mechanism of psychiatric disorders

We use animal models and cellular models to help our clients analyze the changes and roles of inflammatory factors, immune cells, autoantibodies, and other immune indicators in the development of mental illness. These findings help to elucidate the brain's role in regulating the immune system and identify potential targets.

• Biomarker screening and validation

We help our clients identify potential biomarkers for psychiatric disorders and validate them based on immune mechanism studies. These biomarkers may include markers of blood-brain barrier disruption, demyelination, oxidative stress and excitotoxicity, axonal/neuronal damage, gliosis, remyelination, and repair. In addition, markers of altered immune function such as cytokines, chemokines, antibodies, adhesion molecules, antigen presentation, and changes in cellular subpopulations are also included. We will provide the basis for early diagnosis of psychiatric disorders and the development of innovative therapies.

• Screening and validation of immune modulators

We leverage the insights gained from immune mechanism-based studies in conjunction with high-throughput screening to assist clients in identifying drug candidates with immunomodulatory effects. Furthermore, we employ in vitro cellular models and in vivo animal experiments to assist our clients in accurately assessing the effects of drug candidates on immune markers and neurological function. This enables the development of innovative therapies for psychiatric disorders.

Our Advanced Technologies

• Multi-omics technology: Using multi-omics technology, identify and discover immune gene expression associated with psychiatric disorders, gene expression profiles associated with neuroimmune responses, and immune-associated proteins.
• Immunohistochemistry and flow cytometry: detection and quantification of immune cell types and their activity status in tissues and blood by labeling specific antibodies.
• Cell culture and co-culture: using cell models to simulate the interactions between the immune and nervous systems in vitro and to study signal transduction and reciprocal networks between cells.
• Animal model establishment: The study of immune mechanisms, screening of biomarkers, validation as well as screening and evaluation of immunomodulatory candidates through the establishment of models of psychiatric disorders.

Service Process at Ace Therapeutics

• Project consulting
• Program design
• Experiment execution
• Data analysis
• Delivery of results

The experienced professionals at Ace Therapeutics are dedicated to providing comprehensive research services on the neuroimmune mechanisms associated with psychiatric disorders by utilizing our extensive expertise in the field of psychiatric disorders and immunology. Please contact us for more details and we will be happy to assist you.

References

1. Hodes, G. E., et al. Neuroimmune mechanisms of depression. Nature neuroscience. 18.10 (2015): 1386-1393.
2. Pape, K.; et al. Immunoneuropsychiatry-novel perspectives on brain disorders. Nature Reviews Neurology. 15.6 (2019): 317-328.
3. Kokkosis, A. G.; et al. Neuroimmune mechanisms and sex/gender-dependent effects in the pathophysiology of mental disorders. Journal of Pharmacology and Experimental Therapeutics. 375.1 (2020): 175-192.
4. Bennett, F. C.; et al. The immune system and psychiatric disease: a basic science perspective. Clinical & Experimental Immunology. 197.3 (2019): 294-307.
5. Herman, F. J.; et al. Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets. British Journal of Pharmacology. 176.18 (2019): 3558-3584.

Related Services